Amid rising prices for multiple sclerosis medicines, a new study finds that out-of-pocket costs rose substantially in recent years, especially for people with high-deductible plans. And the findings add to growing concerns of the effects of increased spending on patients.

Specifically, multiple sclerosis patients paid $15 a month average out-of-pocket costs in 2004, but that jumped to an average of $309 a month by 2016, a 20-fold increase over a 12-year period. Meanwhile, patients with a high-deductible plan paid an average of $661 per month compared to $246 a month for those not in a high-deductible plan two years ago, according to the study published in Neurology.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • If we had ONE national health system, we wouldn’t have to have physicians wishing they could get “patient-specific out-of-pocket cost information” because it would be the same for everyone.

  • The high costs of new drugs is being driven by exponentially increasing drug development costs,mostly due to increasing regulatory demands. Since only 2-3 out of 10 new drugs that reach the market ever recover their development costs, the best-selling ones must be priced higher to make up for them. Until soaring regulatory costs are addressed, it’s going to be tough to lower drugs prices without derailing innovation. Some of the details appear elsewhere on STAT:

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy